New combo therapy aims to slow advanced liver cancer
Disease control
Recruiting now
This study tests whether adding a targeted drug (apatinib) and an immunotherapy (camrelizumab) to a standard liver cancer treatment (TACE) can better control cancer growth in people whose liver cancer cannot be removed by surgery. About 101 adults with intermediate or advanced li…
Phase: PHASE3 • Sponsor: Guohui Xu • Aim: Disease control
Last updated Apr 30, 2026 15:51 UTC